December 2024 Letter to Shareholders [Yahoo! Finance]
CYTODYN INC (CYDY)
NASDAQ:AMEX Investor Relations:
ir.cytodyn.com
Company Research
Source: Yahoo! Finance
The company is moving forward with three indications associated with chronic inflammation, including the treatment of MASH, Long Covid, and Alzheimer's disease. The company has finalized the protocol for a pilot study of leronlimab in the treatment of patients with mild to moderate Alzheimer's disease, which is fully funded by an outside foundation. Was this helpful? Yes No What is the current status of the company's oncology programs? The company has received FDA clearance to initiate a Phase II study of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer (CRC). Enrollment efforts are set to begin in January. Additionally, the company is launching two preclinical studies in triple-negative breast cancer (TNBC) and is exploring the potential of leronlimab in the treatment of glioblastoma (GBM)..') Was this helpful? Yes No What are the company's plans and priorities for 2025? The company will prioritize oncology in 2025, with a
Show less
Read more
Impact Snapshot
Event Time:
CYDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYDY alerts
High impacting CYTODYN INC news events
Weekly update
A roundup of the hottest topics
CYDY
News
- December 2024 Letter to ShareholdersGlobeNewswire
- 2 ex-CEOs of Washington biotech company face 20 years after fraud convictions [Yahoo! Finance]Yahoo! Finance
- CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology [Yahoo! Finance]Yahoo! Finance
- CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in OncologyGlobeNewswire
- CytoDyn Phase 2 study of leronlimab cleared by FDA [Seeking Alpha]Seeking Alpha
CYDY
Sec Filings
- 11/22/24 - Form 8-K
- 10/30/24 - Form 4
- 10/30/24 - Form 4
- CYDY's page on the SEC website